Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TICAM2 antisense RNA 1 (TICAM2-AS1) is a non-coding RNA molecule transcribed from the antisense strand of the TICAM2 gene[4]. Unlike its protein-coding counterpart TICAM2, which functions as an adaptor molecule in innate immune signaling pathways involving Toll-like receptors and type I interferon induction[1], there is limited publicly available functional information on TICAM2-AS1. In general, antisense long non-coding RNAs like TICAM2-AS1 can modulate the expression of their sense gene (TICAM2) and may be involved in regulatory processes relevant to immunity, disease, or development, but specific biological roles, disease associations, and molecular functions for this particular antisense RNA remain uncharacterized[6]. No known drugs, biomarkers, or significant disease associations for TICAM2-AS1 have been reported in the scientific literature, and it is not currently recognized as a direct therapeutic target[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TICAM2 antisense RNA 1 (TICAM2-AS1).